Lateral Flow Assays Market 2026-2035
Description
Lateral Flow Assays Market Size, Share & Trends Analysis By Product (Kits & Reagents, Lateral Flow Readers, and Mobile Readers), By Technique (Sandwich Assays, Competitive Assays, and Multiplex Detection Assay), By Application (Clinical testing, Veterinary Diagnostics), By End-User (Hospitals and Diagnostic Centres, Home Care, Pharmaceuticals and Biotechnology Companies) Forecast Period, (2026-2035)
Industry Overview
Lateral flow assays market is expected to reach approximately $15.7 billion by 2035, growing at a CAGR of 7.0% from 2026 to 2035, up from $8.1 billion in 2025. The global lateral flow assays market is experiencing steady growth driven by the increasing reliance on rapid diagnostic solutions across healthcare systems. Greater emphasis on early disease identification and timely clinical decision-making has strengthened the adoption of these assays in routine medical practice. Advances in assay design have improved analytical reliability, supporting their use beyond preliminary screening applications. In addition, expanding diagnostic access in outpatient and decentralized settings has reinforced demand for compact and efficient testing formats. The rising need for cost-effective diagnostic tools has further supported commercial uptake in both developed and emerging markets.
Market Dynamics
Expansion of Home-Based and Point-of-Care Testing
The global lateral flow assays market is increasingly shaped by the growing adoption of home-based and point-of-care diagnostic testing. Demand is rising for rapid, easy-to-use assays that deliver results without the need for centralized laboratory infrastructure. This trend is supported by the higher prevalence of infectious and chronic diseases and the need for early diagnosis. Healthcare systems are also encouraging decentralized testing to reduce hospital burden and turnaround times. Manufacturers are responding by developing user-friendly kits with improved sensitivity and stability. As a result, home care and near-patient testing applications are becoming a significant revenue contributor to the market.
Technological Advancements in Multiplex and Reader-Integrated Assays
Technological innovation is driving the development of multiplex lateral flow assays and reader-integrated platforms. Companies are investing in assays capable of detecting multiple analytes simultaneously, improving clinical efficiency and diagnostic accuracy. The integration of digital and mobile readers enables quantitative interpretation, data storage, and connectivity with healthcare systems. These advancements enhance the clinical utility of lateral flow assays beyond traditional qualitative testing. Adoption is particularly strong in hospitals, diagnostic centers, and pharmaceutical research settings. Consequently, technologically advanced assays and readers are expected to support sustained market growth over the forecast period.
Market Segmentation
The growth of the global lateral flow assays market is strongly supported by sustained demand for kits and reagents. These products account for recurring purchases, as they are consumed with every test performed across clinical and non-clinical settings. Continuous improvements in formulation stability and shelf life have enhanced their commercial viability. Manufacturers are also expanding assay menus, which increases repeat procurement by end users. Pricing accessibility compared to laboratory-based alternatives has further strengthened adoption. As a result, kits and reagents remain the primary revenue-generating component of the market.
Hospitals and Diagnostic Centres: A Key Segment in Market Growth
Hospitals and diagnostic centres play a central role in the expansion of the lateral flow assays market due to their high testing volumes. These facilities rely on rapid diagnostic tools to support timely patient management and workflow efficiency. Increasing outpatient visits and emergency testing requirements have reinforced routine usage of lateral flow assays. Institutional procurement policies favor standardized and validated testing formats, supporting consistent demand. Diagnostic centres also benefit from faster turnaround times, which improves operational throughput. This sustained institutional adoption continues to support steady market growth.
Regional Outlook
The global lateral flow assays market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing Diagnostic Testing Demand in Asia-Pacific
The Asia-Pacific lateral flow assays market is growing as access to diagnostic testing continues to improve across the region. Expanding healthcare coverage and rising investments in diagnostic capabilities have increased product demand. Population growth and higher disease screening initiatives have further strengthened testing volumes. Local manufacturing and cost-effective product availability support wider adoption in both urban and semi-urban settings. Government-led health programs also contribute to increased utilization of rapid diagnostic assays. Together, these conditions are driving sustained market expansion in Asia-Pacific.
North America Region Dominates the Market with Major Share
The North America lateral flow assays market is expanding due to strong adoption within the established healthcare infrastructure. High diagnostic spending and widespread availability of point-of-care testing have supported consistent product uptake. Regulatory clarity and reimbursement mechanisms have encouraged the use of rapid diagnostic assays in clinical practice. The region also benefits from the presence of major manufacturers and continuous product innovation. Hospitals and outpatient facilities increasingly integrate rapid tests into standard care pathways. These factors collectively contribute to stable revenue growth across the region.
Market Players Outlook
The major companies operating in the global lateral flow assays market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
Lateral flow assays market is expected to reach approximately $15.7 billion by 2035, growing at a CAGR of 7.0% from 2026 to 2035, up from $8.1 billion in 2025. The global lateral flow assays market is experiencing steady growth driven by the increasing reliance on rapid diagnostic solutions across healthcare systems. Greater emphasis on early disease identification and timely clinical decision-making has strengthened the adoption of these assays in routine medical practice. Advances in assay design have improved analytical reliability, supporting their use beyond preliminary screening applications. In addition, expanding diagnostic access in outpatient and decentralized settings has reinforced demand for compact and efficient testing formats. The rising need for cost-effective diagnostic tools has further supported commercial uptake in both developed and emerging markets.
Market Dynamics
Expansion of Home-Based and Point-of-Care Testing
The global lateral flow assays market is increasingly shaped by the growing adoption of home-based and point-of-care diagnostic testing. Demand is rising for rapid, easy-to-use assays that deliver results without the need for centralized laboratory infrastructure. This trend is supported by the higher prevalence of infectious and chronic diseases and the need for early diagnosis. Healthcare systems are also encouraging decentralized testing to reduce hospital burden and turnaround times. Manufacturers are responding by developing user-friendly kits with improved sensitivity and stability. As a result, home care and near-patient testing applications are becoming a significant revenue contributor to the market.
Technological Advancements in Multiplex and Reader-Integrated Assays
Technological innovation is driving the development of multiplex lateral flow assays and reader-integrated platforms. Companies are investing in assays capable of detecting multiple analytes simultaneously, improving clinical efficiency and diagnostic accuracy. The integration of digital and mobile readers enables quantitative interpretation, data storage, and connectivity with healthcare systems. These advancements enhance the clinical utility of lateral flow assays beyond traditional qualitative testing. Adoption is particularly strong in hospitals, diagnostic centers, and pharmaceutical research settings. Consequently, technologically advanced assays and readers are expected to support sustained market growth over the forecast period.
Market Segmentation
- Based on the product, the market is segmented into kits & reagents, lateral flow readers, and mobile readers.
- Based on the technique, the market is segmented into sandwich assays, competitive assays, and multiplex detection assays.
- Based on the application, the market is segmented into clinical testing and veterinary diagnostics.
- Based on the technique, the market is segmented into hospitals and diagnostic centres, home care, pharmaceuticals, and biotechnology companies.
The growth of the global lateral flow assays market is strongly supported by sustained demand for kits and reagents. These products account for recurring purchases, as they are consumed with every test performed across clinical and non-clinical settings. Continuous improvements in formulation stability and shelf life have enhanced their commercial viability. Manufacturers are also expanding assay menus, which increases repeat procurement by end users. Pricing accessibility compared to laboratory-based alternatives has further strengthened adoption. As a result, kits and reagents remain the primary revenue-generating component of the market.
Hospitals and Diagnostic Centres: A Key Segment in Market Growth
Hospitals and diagnostic centres play a central role in the expansion of the lateral flow assays market due to their high testing volumes. These facilities rely on rapid diagnostic tools to support timely patient management and workflow efficiency. Increasing outpatient visits and emergency testing requirements have reinforced routine usage of lateral flow assays. Institutional procurement policies favor standardized and validated testing formats, supporting consistent demand. Diagnostic centres also benefit from faster turnaround times, which improves operational throughput. This sustained institutional adoption continues to support steady market growth.
Regional Outlook
The global lateral flow assays market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing Diagnostic Testing Demand in Asia-Pacific
The Asia-Pacific lateral flow assays market is growing as access to diagnostic testing continues to improve across the region. Expanding healthcare coverage and rising investments in diagnostic capabilities have increased product demand. Population growth and higher disease screening initiatives have further strengthened testing volumes. Local manufacturing and cost-effective product availability support wider adoption in both urban and semi-urban settings. Government-led health programs also contribute to increased utilization of rapid diagnostic assays. Together, these conditions are driving sustained market expansion in Asia-Pacific.
North America Region Dominates the Market with Major Share
The North America lateral flow assays market is expanding due to strong adoption within the established healthcare infrastructure. High diagnostic spending and widespread availability of point-of-care testing have supported consistent product uptake. Regulatory clarity and reimbursement mechanisms have encouraged the use of rapid diagnostic assays in clinical practice. The region also benefits from the presence of major manufacturers and continuous product innovation. Hospitals and outpatient facilities increasingly integrate rapid tests into standard care pathways. These factors collectively contribute to stable revenue growth across the region.
Market Players Outlook
The major companies operating in the global lateral flow assays market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In November 2025, Sapphiros announces a strategic agreement with Roche, providing Roche access to 1 billion lateral flow tests and access to future molecular point-of-care tests. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros’ 5 billion unit capacity proprietary manufacturing process
- In July 2025, VolitionRx Ltd., a multi-national epigenetics company, announced it had demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program, tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global lateral flow assays market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
288 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Lateral Flow Assays Market Sales Analysis – Product Technique Application End-User ($ Million)
- Lateral Flow Assays Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Lateral Flow Assays Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the Lateral Flow Assays Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global Lateral Flow Assays Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Lateral Flow Assays Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global Lateral Flow Assays Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – Lateral Flow Assays Market Revenue and Share by Manufacturers
- Lateral Flow Assays Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Becton, Dickinson and Company
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Siemens Healthineers
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific Inc.
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. Global Lateral Flow Assays Market Sales Analysis by Product ($ Million)
- 5.1. Kits & Reagents
- 5.2. Lateral Flow Readers
- 5.3. Mobile Readers
- 6. Global Lateral Flow Assays Market Sales Analysis by Technique ($ Million)
- 6.1. Sandwich Assays
- 6.2. Competitive Assays
- 6.3. Multiplex Detection Assay
- 7. Global Lateral Flow Assays Market Sales Analysis by Application ($ Million)
- 7.1. Clinical Testing
- 7.1.1. Infectious Diseases Testing
- 7.1.2. Pregnancy & Fertility Testing
- 7.1.3. Cardiac Markers
- 7.1.4. Cholesterol/Lipid Testing
- 7.2. Veterinary Diagnostics
- 7.2.1. Drug Development & Quality Testing
- 7.2.2. Food Safety & Environmental Safety
- 8. Global Lateral Flow Assays Market Sales Analysis by End-User ($ Million)
- 8.1. Hospitals and Diagnostic Centres
- 8.2. Home Care
- 8.3. Pharmaceuticals and Biotechnology Companies
- 9. Regional Analysis
- 9.1. North American Lateral Flow Assays Market Sales Analysis – Product Technique Application End-User Country ($ Million)
- Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
- 9.2. European Lateral Flow Assays Market Sales Analysis – Product Technique Application End-User Country ($ Million)
- Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
- 9.3. Asia-Pacific Lateral Flow Assays Market Sales Analysis – Product Technique Application End-User Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 9.3.7. Rest of Asia-Pacific
- 9.4. Rest of the World Lateral Flow Assays Market Sales Analysis – Product Technique Application End-User Country ($ Million)
- Macroeconomic Factors for Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa
- 10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
- 10.2. Abcam Plc
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
- 10.3. Abingdon Health Ltd
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
- 10.4. Axxin (lateral flow reader technologies specialist)
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
- 10.5. Becton, Dickinson and Company (BD)
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
- 10.6. Bioassay Works LLC
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
- 10.7. bioMérieux SA
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
- 10.8. Bio-Rad Laboratories, Inc.
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
- 10.9. Chembio Diagnostics, Inc.
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
- 10.10. F. Hoffmann-La Roche Ltd.
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
- 10.11. Hologic, Inc.
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
- 10.12. Lumos Diagnostics (or Lumos Diagnostics LLC)
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
- 10.13. Merck KGaA
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
- 10.14. OraSure Technologies, Inc.
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
- 10.15. PerkinElmer, Inc.
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
- 10.16. QIAGEN N.V.
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
- 10.17. Quidel Corporation
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
- 10.18. Siemens Healthineers
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
- 10.19. Surmodics, Inc.
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
- 10.20. Thermo Fisher Scientific Inc.
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
